Pfizer’s Xeljanz Could See Narrower Label And New REMS Due To CV And Malignancy Risks

The US FDA will ponder its regulatory options now that final data are in from a long-term postmarketing study showing tofacitinib is associated with a higher rate of major adverse cardiovascular events and malignancies compared with TNF-inhibitors.

x-ray hands, rheumatoid arthritis
A Xeljanz study in high-risk rheumatoid arthritis patients has raised safety concerns. • Source: Shutterstock

The US Food and Drug Administration will weigh its regulatory its options for Pfizer Inc.’s Xeljanz (tofacitinib) in light of cardiovascular and malignancy risks identified in a long-term, postmarketing safety trial of the JAK-inhibitor in rheumatoid arthritis patients.

The FDA said it is evaluating the results received to date on CV and malignancy primary endpoints in the ORAL...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America